![](https://investorshub.advfn.com/uicon/350406.png?cb=1547729749)
Saturday, March 29, 2014 9:56:41 AM
ELTP will get pushed over the weekend
Top O' the early Saturday morning my beautiful ELTPers!!
And what a glorious morning it is in the land of ELTP. I hear tell little old Elite has hired the beautiful Ms.Barbara Ellison since I've been away. I particularly like her previous international experience with regulatory affairs. Say anybody think that has anything to do with the Canadian Patent Elite just garnered? Highest opioid revenue generating countries in the World: the United States and Canada. Check and double check. Cha Ching. What's next a European ART patent. Notice the lack of question mark.
http://www.elitepharma.com/patents.asp
And what is holding up the FDA in terms of handing Elite its 3rd ART patent? New FDA procedural red tape. Go figure. Guess we know who is gumming up the works for our next pivotal BE study launch. Just put a tax penalty on all company's who illegally short sell stocks and put the proceeds toward additional FDA hires and regulatory affairs. Or should that money actually go to the SEC. The SEC it is.
What does that make for employees now 32?.... with another position: Lead Operator yet to hire? Whew seems only yesterday Elite only had 16 employees and zero products on the market. Now 8 and Isradipine's CBE 30 has been filed. Not a big money maker unless Marty McFly has anything to say about it. Still every million dollar quarterly revenue increase mattes. Help me out BMT what does that make 5 stellar revenue quarters one after the other?
CFP on operations and moving in on R&D costs as I type! Dantrolene, Loxapine, and Hydroxyzine next on the CBE 30 docket. And as the DDoctor has mentioned Hydroxyzine could bring in a little money. What was it $55 million IMS yearly sales per Mylan PR in 2010. We're making tablets...so 12 other tablet makers currently including Watson. Not a killer product but perhaps Elite can garner $4 -6 million on it. Elite used to be CFP minus R&D costs on $4 million alone. Probably more like $6 million now considering all the new infrastructure and machinery Doug Plasche is overseeing.
NOW the Proxy Vote. Interesting situation and clearly Nasrat is playing Chess like a master. He is sending a message IMO. We would like a Big Pharma partner but you best sign on bc the ART Monorail Train is leaving the station and YOU best have a ticket!! ART is coming!!!
With or without YOU!!
Anyone like to see the previous Proxy Vote of 2011 and compare it to the 2014? Here they are. 355,517,558 in 2011 and now they want 995,000,000 shares in 2014. Almost 3 times the amount of AS from 2011 to 2014 IF passed. Well what I can tell you is the PPS at the time of the Proxy Vote in 2011 was .1295. So Elite has tripled their PPS since the previous Proxy Vote. Me I voted YES on the previous proxy and I'm voting YES this time around as well. Let's just hope WE aren't asked for another vote in 2017 unless Elite is sitting squarely on the NASDAQ at $5 a share!
Nasrat is a Master at negotiations and MY BET we hear from him sooner than later regarding the Proxy Vote.
http://www.elitepharma.com/ELTP%20FY2011%20DEF14A.pdf
http://archive.fast-edgar.com//20140318/A8A2N22CZC22L2ZU222S2WZA9L6C2B22Z262/
My BEST as always LONGS. It's GOOD to be back!!
![smile](/images/emoticon01.gif)
Couch
The Helper
Fear Uncertainty and Doubt FUD It Ain't Going To Work Here Anymore. Notice the lack of question mark.
Recent ELTP News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 08:07:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2024 08:30:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 09:55:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/29/2023 07:21:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/26/2023 09:20:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/12/2023 09:20:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/28/2023 12:05:38 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/27/2023 11:58:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/27/2023 11:50:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration with ZenaDrone • InvestorsHub NewsWire • 11/16/2023 12:32:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/25/2023 08:15:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/07/2023 08:05:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2023 09:30:05 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 07/31/2023 08:20:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/17/2023 08:15:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/29/2023 09:15:09 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 06/29/2023 08:43:45 PM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM
Bemax Inc. Positions to Capitalize on Industry Growth with New Improved Quality of Mother's Touch® Disposable Diapers • BMXC • Jun 24, 2024 8:00 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM